Lördag 26 April | 12:18:45 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-06-17 08:00 Bokslutskommuniké 2026
2026-03-18 08:00 Kvartalsrapport 2026-Q3
2025-12-18 08:00 Kvartalsrapport 2026-Q2
2025-09-16 N/A Årsstämma
2025-09-11 08:00 Kvartalsrapport 2026-Q1
2025-06-18 08:00 Bokslutskommuniké 2025
2025-03-13 - Kvartalsrapport 2025-Q3
2024-12-12 - Kvartalsrapport 2025-Q2
2024-09-18 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2024-09-17 - Årsstämma
2024-09-12 - Kvartalsrapport 2025-Q1
2024-07-15 - Extra Bolagsstämma 2025
2024-06-18 - Bokslutskommuniké 2024
2024-03-14 - Kvartalsrapport 2024-Q3
2023-11-28 - Kvartalsrapport 2024-Q2
2023-09-06 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2023-09-06 - Kvartalsrapport 2024-Q1
2023-09-05 - Årsstämma
2023-06-21 - Bokslutskommuniké 2023
2023-05-17 - Extra Bolagsstämma 2024
2023-03-16 - Kvartalsrapport 2023-Q3
2022-12-15 - Kvartalsrapport 2023-Q2
2022-11-07 - Extra Bolagsstämma 2022
2022-09-01 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2022-08-31 - Årsstämma
2022-08-31 - Kvartalsrapport 2023-Q1
2022-06-16 - Bokslutskommuniké 2022
2022-03-15 - Kvartalsrapport 2022-Q3
2021-12-01 - Kvartalsrapport 2022-Q2
2021-09-01 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2021-08-31 - Årsstämma
2021-08-31 - Kvartalsrapport 2022-Q1
2021-06-17 - Bokslutskommuniké 2021
2021-03-18 - Kvartalsrapport 2021-Q3
2020-12-03 - Kvartalsrapport 2021-Q2
2020-08-28 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2020-08-27 - Årsstämma
2020-08-27 - Kvartalsrapport 2021-Q1
2020-06-12 - Bokslutskommuniké 2020
2020-03-12 - Kvartalsrapport 2020-Q3
2019-12-05 - Kvartalsrapport 2020-Q2
2019-08-30 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2019-08-29 - Årsstämma
2019-08-29 - Kvartalsrapport 2020-Q1
2019-06-14 - Bokslutskommuniké 2019
2019-05-02 - Extra Bolagsstämma 2020
2019-03-21 - Kvartalsrapport 2019-Q3
2018-12-13 - Kvartalsrapport 2019-Q2
2018-08-31 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2018-08-30 - Årsstämma
2018-08-30 - Kvartalsrapport 2019-Q1
2018-06-15 - Bokslutskommuniké 2018
2018-03-21 - Kvartalsrapport 2018-Q3
2017-12-19 - Kvartalsrapport 2018-Q2
2017-09-01 - X-dag ordinarie utdelning BIOVIC B 0.00 SEK
2017-08-31 - Årsstämma
2017-08-31 - Kvartalsrapport 2018-Q1
2017-06-14 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Biovica International är ett läkemedelsbolag som inriktar sin forskning mot cancerbehandling. Bolaget utvecklar metoder för mätning utav cellproliferation, där testet tas via blodprov. Proven analyserar risken för utvecklingen av enzymet tymidinkinas, en enzym som har koppling till tumörers tillväxt. Huvudfokus återfinns inom behandling av bröstcancer. Bolaget grundades 2008 och har sitt huvudkontor i Uppsala.
2022-11-07 14:00:00

The extra general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 7 November 2022 in Stockholm and the following resolutions were passed by the meeting.

RIGHTS ISSUE
The extra general meeting resolved to approve the board of directors resolution from 18 October 2022 on a rights issue of a maximum of 17,153,022 B shares. The total increase of the Company's share capital can amount to a maximum of SEK 1,143,534.80.

The subscription price for the new B shares is SEK 8.65 per share, in total SEK 148,373,640.30 if all shares are subscribed for.

Those who on the record date 15 November 2022 are recorded as a holder of shares in the share register kept by Euroclear Sweden AB shall have a preferential right, to subscribe for new shares at a subscription price of SEK 8.65 per B share. Shareholders receive one (1) subscription right for each share held as of the record date. Ten (10) subscription rights entitle the holder to subscribe for six (6) new B shares in the rights issue.

Subscription for shares with subscription rights shall be made by payment in cash during the period from 21 November 2022 up until and including 5 December 2022. Subscription for shares without subscription rights shall be made on a subscription list during the period from 21 November 2022 up until and including 5 December 2022. Payment for shares subscribed for without subscription rights shall be made no later than three days following issue of a transfer note that include a decision of allotment.

If all of the new shares are not subscribed for with subscription rights, the board will decide on allotment of new shares subscribed for without subscription rights. Allotment will then be made firstly to persons who have applied for subscription without subscription rights and who have subscribed for shares with subscription rights, regardless of whether or not the subscriber was a shareholder on the record date, and in case of oversubscription, allocation shall be made in relation to the total number of shares allotted through exercise of subscription rights, and to the extent that this is not possible, by drawing of lots. Secondly, allocation shall be made to other persons who have applied for subscription without subscription rights, and in the case of oversubscription, pro rata to the new number of shares subscribed for in the application form, and to the extent that this is not possible, by drawing of lots. Finally, allotment of the remaining shares shall be made to the investors who have provided guarantees and in accordance with the conditions of their respective guarantee.

For detailed terms regarding the resolution at the extra general meeting as described above, please refer to the notice which is available on the Company's website, www.biovica.com.